全球首针！针对奥密克戎！First Omicron-specific vaccine administered in China

5月1日，一名临床试验志愿者在杭州注射奥密克戎变异株新冠病毒灭活疫苗。新华社发

5月1日下午，由国药集团中国生物北京生物制品研究所研发的奥密克戎变异株新冠病毒灭活疫苗临床研究，正式在浙江省杭州市完成第一剂接种。这也是全球首支针对奥密克戎变异株进入临床试验的新冠病毒灭活疫苗。

China began clinical trials for a vaccine designed specifically against the Omicron variant in Hangzhou, Zhejiang province, on Sunday, making it the first vaccine of its kind to enter human trials in the world against the highly transmissible COVID-19 strain.

China National Biotech Group, a subsidiary of Sinopharm, has been developing the vaccine since December 2021, the company said in a news release on Monday.

5月1日，一名临床试验志愿者在杭州注射奥密克戎变异株新冠病毒灭活疫苗。新华社发

此次在树兰（杭州）医院开展临床研究的奥株疫苗需要接种两剂，将评价奥株疫苗在未接种新冠病毒疫苗18岁及以上人群中的安全性和免疫原性。此临床研究数据获批后，未接种过新冠疫苗的空白人群可直接接种奥株疫苗。

4月22日拍摄的国药集团中国生物北京生物制品研究所研发的奥密克戎变异株新冠病毒灭活疫苗。新华社发

“奥密克戎变异株的疫苗研发非常重要，当然原来的疫苗还是有效的，但是针对变异株的疫苗研发以后，将可能会有更好的免疫效果。这个也证明了中国在抗疫工作当中的速度、中国的效率。” 中国工程院院士李兰娟表示，相信通过严格的临床研究，对疫苗的安全性、有效性可以进一步证明，来保障以后疫苗的应用。

来源：新华社、北京日报（记者：袁璐）

Omicron-specific Sinopharm vaccine administered in China’s Hangzhou

Sinopharm's Omicron-specific inactivated vaccine is the world’s first

Web Desk Updated: May 03, 2022 14:04 IST

The first dose of COVID-19 inactivated vaccine specifically against the Omicron variant was administered on Sunday during a clinical trial in Hangzhou, East China’s Zhejiang Province, report Global Times.

The world's first inactivated vaccine against Omicron, produced by China’s state-run vaccine producer Sinopharm, has brought hope to people in the regions hit by the highly transmissible variant. 

Omicron that causes more severe disease compared to infections with other variants remains a serious threat to people’s health.

Zheng Zhongwei, head of China's COVID-19 vaccine development task force and official with the National Health Commission, previously told media that China's vaccine development team has been on the move since the Omicron variant emerged. “The basic principle we follow is ‘Better prepared than unprepared.’”

Top Chinese epidemiologists praising the new vaccine as being of great significance. Li Lanjuan, renowned Chinese epidemiologist based in Hangzhou, told Global Times that the previous version of the vaccine is still effective, but the development of a specific vaccine against the mutant strain will provide better immunity.

Li explained that the research into and development of the vaccine against the Omicron started on December 9, 2021, and was approved for clinical trial by the National Medical Products Administration on April 26, 2022. 

People who had not received a Covid-19 vaccine or been infected with the virus were selected as volunteers for the vaccination as they did not have antibodies. “I want to strengthen my immunity and meanwhile contribute to society… I feel good so far,” the volunteer told media. 

Li said the next step would be to conduct clinical trials on people who have already been vaccinated to see if it is also more effective.

(source: The Week Magazine. https://www.theweek.in/news/health/2022/05/03/omicron-specific-sinopharm-vaccine-administered-in-chinas-hangzh.html)

相关文章：